Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug3786 | Stool collection or fecal swab Wiki | 0.71 |
| drug2202 | Low or upper respiratory tract sample Wiki | 0.71 |
| drug4647 | phone call Wiki | 0.71 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| D045169 | Severe Acute Respiratory Syndrome NIH | 0.06 |
| D003141 | Communicable Diseases NIH | 0.05 |
| D018352 | Coronavirus Infections NIH | 0.05 |
| Name (Synonyms) | Correlation |
|---|
Navigate: Correlations HPO
There are 2 clinical trials
The purpose of this study is to test whether Fisetin, a senolytic drug, can assist in preventing an increase in the disease's progression and alleviate complications of coronavirus due to an excessive inflammatory reaction.
Description: Number of participants to experience serious adverse events and hypersensitivity reactions.
Measure: Serious Adverse Events Time: 6 monthsDescription: change in oxygenation levels as measured by S/F ratio (SPO2/FiO2)
Measure: Change in oxygenation status Time: baseline, Day 3, 7, 10, 14, 17 and 30; Months 3 and 6Description: Number of participants to progress to severe or critical classification measure by the WHO/ NIH Baseline Severity Classification criteria descriptions of SARS-CoV-2 infection without symptoms, Mild COVID-19 (CoV), Moderate CoV, Severe CoV and Critical CoV
Measure: COVID-19 Severity Category Time: 6 monthsThe purpose of this study is to test whether Fisetin, a senolytic drug, can assist in preventing an increase in the disease's progression and alleviate complications of coronavirus due to an excessive inflammatory reaction.
Description: Ordinal Scale for Clinical Improvement (minimum=0 and maximum=8; higher score = worse outcome)
Measure: Change in COVID-19 Severity Time: baseline, Day 2, 7, 10, 14, 17, 30, 90 and 180Alphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports